LFCR

Lifecore Biomedical

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

-

Business Summary

Lifecore Biomedical is a contract development and manufacturing organization (CDMO) specializing in the production of sterile, injectable-grade pharmaceutical products. The company provides services for the development, fill, and finish of complex drug products in syringes and vials for pharmaceutical and medical device companies.

 


Analyze LFCR on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$269

Forward P/E

-

PEG

-

PRICE TO SALES

1.9

PRICE TO BOOK

119.6

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.27

Next Year EPS Growth Estimate

-$0.55

Next Year Revenue Growth Estimate

13.10%

Return on Equity (ROE)

-3320.30%

FREE CASH FLOW

Operating Margin

-9.30%

Debt-to-Equity

97.9

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze LFCR on TradingView

Gainseekers Quantitative Analysis

Summary

Lifecore Biomedical is a $269 million market cap company currently experiencing unprofitability, with an EPS of -$1.27 and a negative Operating Margin of -9.30%. The firm carries a high Debt / Equity ratio of 97.9 and trades at a Price / Book multiple of 119.6. Despite these challenges, analysts forecast Sales Growth Next Year of 13.10%.

AI Exposure / Tech Reliance

The provided financial data does not contain any metrics related to AI exposure or specific technological reliance.

The Bull Case

The bull case is supported by a projected Sales Growth Next Year of 13.10% and a Mean Consensus Target Price of $9.25. Additionally, the company has a high Institutional Ownership % of 76.40%.

The Bear Case

The bear case is centered on significant unprofitability, including a Return on Equity of -3320.30% and an EPS of -$1.27. Financial risks are highlighted by a Debt / Equity ratio of 97.9 and a Short % of Float of 12.20%.

Market Sentiment & Smart Money

Short Interest %

12.20%

Analyst Consensus

2.33

Average Analyst Price Target

$9.25

Institutional Ownership %

76.40%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.